ATAI
Atai Life Sciences N.V. [ATAI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ATAI Stock Summary
Top 10 Correlated ETFs
ATAI
Top 10 Correlated Stocks
ATAI
In the News
ATAI Financial details
ATAI Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0.13 | 0 | 0 | |
| Net income per share | -3.23 | -17.57 | -0.83 | -0.91 | -0.25 | |
| Operating cash flow per share | -1.45 | -3.57 | -0.39 | -0.67 | -0.53 | |
| Free cash flow per share | -1.45 | -3.58 | -0.4 | -0.68 | -0.53 | |
| Cash per share | 5.55 | 16.73 | 2.25 | 1.75 | 0.97 | |
| Book value per share | 10.85 | 15.62 | -2.17 | 1.67 | 1.53 | |
| Tangible book value per share | 11.01 | 16.4 | 0.06 | 0.03 | 1.54 | |
| Share holders equity per share | 10.85 | 15.62 | -2.17 | 1.67 | 1.53 | |
| Interest debt per share | 0.03 | 0.37 | 0 | 0.11 | 0.11 | |
| Market cap | 9.91M | 113.08M | 1.23B | 414.21M | 223.96M | |
| Enterprise value | -19.99M | 18.01M | 864.44M | 238.72M | 195.4M | |
| P/E ratio | -0.57 | -1.11 | -9.24 | -2.93 | -5.57 | |
| Price to sales ratio | 0 | 0 | 60.17 | 1.78K | 713.23 | |
| POCF ratio | -1.26 | -5.45 | -19.38 | -3.97 | -2.66 | |
| PFCF ratio | -1.26 | -5.43 | -19.04 | -3.93 | -2.64 | |
| P/B Ratio | 0.17 | 1.25 | -3.52 | 1.59 | 0.92 | |
| PTB ratio | 0.17 | 1.25 | -3.52 | 1.59 | 0.92 | |
| EV to sales | 0 | 0 | 42.42 | 1.02K | 622.29 | |
| Enterprise value over EBITDA | -12.65 | -0.18 | -8.24 | -1.66 | -1.56 | |
| EV to operating cash flow | 2.55 | -0.87 | -13.67 | -2.29 | -2.32 | |
| EV to free cash flow | 2.54 | -0.86 | -13.43 | -2.26 | -2.31 | |
| Earnings yield | -1.76 | -0.9 | -0.11 | -0.34 | -0.18 | |
| Free cash flow yield | -0.79 | -0.18 | -0.05 | -0.25 | -0.38 | |
| Debt to equity | 0 | 0.02 | 0 | 0.06 | 0.06 | |
| Debt to assets | 0 | 0.02 | 0 | 0.05 | 0.05 | |
| Net debt to EBITDA | -18.93 | 0.97 | 3.45 | 1.22 | 0.23 | |
| Current ratio | 24.36 | 8.09 | 17.92 | 14.43 | 9.22 | |
| Interest coverage | 0 | 0 | 0 | -75.61 | -47.24 | |
| Income quality | 0.32 | 0.12 | 0.36 | 0.66 | 2.09 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 4.55 | 301.93 | 202.49 | |
| Research and developement to revenue | 0 | 0 | 2.35 | 318.94 | 197.08 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.02 | 0.01 | 0.01 | |
| Capex to revenue | 0 | 0 | -0.06 | -4.39 | -1.88 | |
| Capex to depreciation | -3.17 | -2.46 | -24 | -6.1 | -1.85 | |
| Stock based compensation to revenue | 0 | 0 | 3.11 | 181.87 | 105.04 | |
| Graham number | 28.06 | 78.58 | 6.34 | 5.85 | 2.95 | |
| ROIC | 0.03 | -1.12 | 0.38 | -0.55 | -0.5 | |
| Return on tangible assets | -0.28 | -0.92 | -0.32 | -0.46 | -0.14 | |
| Graham Net | 6.31 | 14.15 | -0.26 | -0.17 | 0.67 | |
| Working capital | 37.54M | 87.25M | 354.15M | 267.25M | 165.47M | |
| Tangible asset value | 59.64M | 95.37M | 9.05M | 5.03M | 244.32M | |
| Net current asset value | 36.67M | 83.37M | -30.03M | -13.27M | 136.43M | |
| Invested capital | 0 | 0.02 | 0 | 0.06 | 0.06 | |
| Average receivables | 0 | 5M | 1.1M | 3.27M | 3.94M | |
| Average payables | 0 | 1.89M | 4.54M | 4.2M | 3.49M | |
| Average inventory | 0 | 315K | 228.5K | -2.82M | -2.82M | |
| Days sales outstanding | 0 | 0 | 16.35 | 8.82K | 2.62K | |
| Days payables outstanding | 41.85K | 46.89K | 46.63K | 5.21K | 5.25K | |
| Days of inventory on hand | 10.52K | 6.95K | 0 | -12.23K | 0 | |
| Receivables turnover | 0 | 0 | 22.32 | 0.04 | 0.14 | |
| Payables turnover | 0.01 | 0.01 | 0.01 | 0.07 | 0.07 | |
| Inventory turnover | 0.03 | 0.05 | 0 | -0.03 | 319K | |
| ROE | -0.3 | -1.12 | 0.38 | -0.54 | -0.17 | |
| Capex per share | 0 | -0.01 | -0.01 | -0.01 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
| Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.29 | -0.21 | -0.21 | 0.28 | -0.12 | |
| Operating cash flow per share | -0.19 | -0.14 | -0.15 | -0.12 | -0.13 | |
| Free cash flow per share | -0.19 | -0.14 | -0.15 | -0.12 | -0.13 | |
| Cash per share | 1.72 | 1.6 | 1.46 | 1.34 | 0.97 | |
| Book value per share | 1.64 | -3.51 | 1.36 | 1.71 | 1.53 | |
| Tangible book value per share | 0.03 | 0.02 | 1.38 | 1.72 | 1.54 | |
| Share holders equity per share | 1.64 | -3.51 | 1.36 | 1.71 | 1.53 | |
| Interest debt per share | 0.09 | 0.11 | 0.11 | 0.11 | 0.1 | |
| Market cap | 422.15M | 281.98M | 267.96M | 200.97M | 223.97M | |
| Enterprise value | 246.66M | 112.81M | 143.58M | 141.15M | 195.41M | |
| P/E ratio | -2.33 | -2.12 | -2.03 | 1.14 | -3.06 | |
| Price to sales ratio | 11.11K | 7.62K | 1.56K | 2.31K | 12.44K | |
| POCF ratio | -13.84 | -13.36 | -11.85 | -10.9 | -10.61 | |
| PFCF ratio | -13.74 | -13.08 | -11.78 | -10.9 | -10.61 | |
| P/B Ratio | 1.62 | -0.52 | 1.26 | 0.75 | 0.92 | |
| PTB ratio | 1.62 | -0.52 | 1.26 | 0.75 | 0.92 | |
| EV to sales | 6.49K | 3.05K | 834.76 | 1.62K | 10.86K | |
| Enterprise value over EBITDA | -6.57 | -3.4 | -4.51 | -5.26 | -5.84 | |
| EV to operating cash flow | -8.09 | -5.34 | -6.35 | -7.66 | -9.26 | |
| EV to free cash flow | -8.03 | -5.23 | -6.31 | -7.66 | -9.26 | |
| Earnings yield | -0.11 | -0.12 | -0.12 | 0.22 | -0.08 | |
| Free cash flow yield | -0.07 | -0.08 | -0.08 | -0.09 | -0.09 | |
| Debt to equity | 0.06 | -0.03 | 0.08 | 0.06 | 0.06 | |
| Debt to assets | 0.05 | 0.06 | 0.07 | 0.05 | 0.05 | |
| Net debt to EBITDA | 4.67 | 5.09 | 3.9 | 2.23 | 0.85 | |
| Current ratio | 14.43 | 12.84 | 13.54 | 11.04 | 9.22 | |
| Interest coverage | 154.59 | -52.31 | -48.42 | -39.12 | -48.57 | |
| Income quality | 0.65 | 0.61 | 0.67 | -0.42 | 1.15 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 413.87 | 377.57 | 96.27 | 156.68 | 1.08K | |
| Research and developement to revenue | 575.68 | 521.11 | 89.98 | 152.76 | 780.83 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0.02 | 0.01 | 0 | 0 | |
| Capex to revenue | -5.87 | -11.97 | -0.74 | -0.02 | -0.56 | |
| Capex to depreciation | -4.21 | -6.82 | -1.62 | -0.03 | -0.1 | |
| Stock based compensation to revenue | 319.47 | 234.11 | 50.94 | 94.86 | 405.83 | |
| Graham number | 3.25 | 4.11 | 2.55 | 3.3 | 1.99 | |
| ROIC | -0.16 | 0.06 | -0.14 | -0.09 | -0.13 | |
| Return on tangible assets | -0.15 | -0.12 | -0.13 | 0.14 | -0.06 | |
| Graham Net | -0.16 | -0.13 | 1.26 | 1.09 | 0.67 | |
| Working capital | 267.25M | 247.06M | 224.84M | 197.65M | 165.47M | |
| Tangible asset value | 5.03M | 3.82M | 215.64M | 268.51M | 244.32M | |
| Net current asset value | -13.27M | -8.97M | 204.81M | 177.64M | 136.43M | |
| Invested capital | 0.06 | -0.03 | 0.08 | 0.06 | 0.06 | |
| Average receivables | 5.49M | 7.24M | 8.94M | 5.27M | 1.89M | |
| Average payables | 2.96M | 3.66M | 4.39M | 4.68M | 5.05M | |
| Average inventory | 537.5K | -2.82M | 0 | 0 | 0.5 | |
| Days sales outstanding | 13.34K | 21.53K | 4.72K | 1.57K | 11.29K | |
| Days payables outstanding | 4.07K | 2.65K | 1.78K | 6.7K | 4.09K | |
| Days of inventory on hand | -9.56K | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0.01 | 0 | 0.02 | 0.06 | 0.01 | |
| Payables turnover | 0.02 | 0.03 | 0.05 | 0.01 | 0.02 | |
| Inventory turnover | -0.01 | 0 | 0 | 0 | 101K | |
| ROE | -0.17 | 0.06 | -0.16 | 0.17 | -0.08 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
ATAI Frequently Asked Questions
What is Atai Life Sciences N.V. stock symbol ?
Atai Life Sciences N.V. is a DE stock and trading under the symbol ATAI
What is Atai Life Sciences N.V. stock quote today ?
Atai Life Sciences N.V. stock price is $1.94 today.
Is Atai Life Sciences N.V. stock public?
Yes, Atai Life Sciences N.V. is a publicly traded company.
Company Profile
- Volume Average 1.62M
- Market Capitalization 381.86M
- Employee 83
- CEO Mr. Florian Brand
- Headquarters Berlin,DE
- IPO Date 2021-06-18
-
Website
https://www.atai.life 
Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
